Abstract:Glucagon-like peptide-2 (GLP-2) is an intestinotrophic hormone produced by intestinal L cells that stimulates proliferation in the intestinal crypt.However, the GLP-2 receptor is not expressed in the crypt but, rather, in subepithelial myofibroblasts that subtend this compartment.Consistent with an indirect mechanism of action of GLP-2, knockout (KO) of insulin-like growth factor-1 (IGF-1) or its intestinal epithelial receptor (IE-IGF-1R) decreases the proliferative effect of GLP-2 in mice.Similarly, administration of a pan-ErbB inhibitor or IE-Erb1 KO decreases GLP-2-induced crypt proliferation, while co-administration of epidermal growth factor (EGF) and GLP-2 in rats and piglets causes an enhanced proliferative effect.Interestingly, it has recently been shown in IEC-6 cells that pre-treatment with EGF before IGF-1 synergistically increases their proliferation.We, therefore, hypothesized that EGF enhances IGF-1-mediated GLP-2-induced proliferation in mice.C57BL/6J mice (n=8-9 per group, males and females) were treated with vehicle or 0.2 mg/g-d h(Gly 2 )GLP-2 (a degradation-resistant human GLP-2 analog); 0.4 mg/g-d murine EGF was given either as a pre-treatment at -3 h and/or as a co-treatment with EGF alone or with the GLP-2, for 11 d (Table 1).Body weight and small intestinal length did not change between the groups.However, small intestinal weight normalized to body weight and to small intestinal length was highest in group 8, the pre+co-EGF plus GLP-2 combination group compared to vehicle (p<0.001).Jejunal crypt-villus height analysis showed that all EGF plus GLP-2 combination treatments (groups 4, 6, 8) were more effective than vehicle, GLP-2 or EGF alone (p<0.05-0.001).Conversely, jejunal EdU uptake assessment demonstrated that GLP-2, but not EGF, induced crypt proliferation.RT-qPCR showed no changes in the expression of either the ligands or their receptors for all test agents.To determine the relationship between EGF-GLP-2 and IGF-1, male and female IE-IGF-1R KO mice (C57Bl/ 6 villin-cre-ER T2+ :IGF-1R fl/fl ) mice and all genetic/tamoxifen controls, were then treated with vehicle or pre+co-EGF, alone or with GLP-2, as above (i.e.groups 1, 2, 7, 8).RT-qPCR on jejunal mucosa confirmed 85% KO of the IE-IGF-1R.Preliminary crypt-villus height results showed that, while the intestinotrophic effects of GLP-2 were blunted in the KO mice, as expected, the KO animals retained the growth effects of pre+coEGF treatment as well as that of pre+co-EGF plus GLP-2.In conclusion, EGF enhances the chronic intestinotrophic effects of GLP-2 through a mechanism other than crypt cell proliferation, although IGF-1R signaling may not be required for EGF-induced proliferation, alone or in combination with GLP-2.These findings have implications with respect to our understanding of the mechanisms of action of both GLP-2 and EGF in the gut.Experiment #1 Treatment Groups

Glucagon‐like Peptide‐2 Activates the Mtor Signaling Through a PI3‐kinase‐Akt‐ Dependent Pathway

Glucagon-Like Peptide-2-Stimulated Protein Synthesis Through the Pi 3-Kinase-dependent Akt-Mtor Signaling Pathway

Intestinal mTOR regulates GLP-1 production in mouse L cells

Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.

Glucagon-Like Peptide-1 Analog-Mediated Protection Against Cholesterol-Induced Apoptosis Via Mammalian Target Of Rapamycin Activation In Pancreatic Beta Tc-6 Cells

mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b

Prostaglandin E 2 Regulates Foxo Activity Via the Akt Pathway: Implications for Pancreatic Islet Beta Cell Dysfunction

Extracellular Glutamine Promotes Intestinal Porcine Epithelial Cell Proliferation via Arf1-mTORC1 Pathway Independently of Rag GTPases

Regulation of gastric hormones by systemic rapamycin.

l -Glutamine enhances enterocyte growth via activation of the mTOR signaling pathway independently of AMPK

The Effects of Glucagon-like Peptide-2 on the Tight Junction and Barrier Function in IPEC-J2 Cells Through Phosphatidylinositol 3-Kinase–protein Kinase B–Mammalian Target of Rapamycin Signaling Pathway

526 – the Role of Tuft Cell Specification and Function in Inflammatory Ileitis

Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake.

Insulin-like Growth Factor-1 (IGF-1) and Leucine Activate Pig Myogenic Satellite Cells Through Mammalian Target of Rapamycin (mtor) Pathway.

Molecular Mechanism of Glucagon Peptide-2 in Stimulating Cell Proliferation and Suppressing Cell Apoptosis

mTORC2 Regulates Lipogenic Gene Expression through PPARγ to Control Lipid Synthesis in Bovine Mammary Epithelial Cells

Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide

mTOR signaling in X/A-like cells contributes to lipid homeostasis in mice.

AMPK-dependent Phosphorylation of the GATOR2 Component WDR24 Suppresses Glucose-Mediated Mtorc1 Activation.

Modulation of the activities of AMP‐activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2‐deoxyglucose

Mtor-Dependent Modulation of Gastric Nesfatin-1/NUCB2